Late Breaking Clinical Trial session of RACE 3 in EHRA 2021 congress
Long term effects of targeted therapy on sinus rhythm maintenance and cardiovascular outcome will be presented at Late Breaking Clinical Trial session on Friday April 23rd.
The RACE 3 study is a randomized, prospective, multicenter center study comparing conventional therapy to targeted therapy of underlying conditions of atrial fibrillation. The study was performed between 2009 and 2021. Data on the first year follow-up have been previously published, and showed that targeted therapy improved maintenance of sinus rhythm.
On the EHRA congress of 2021 data of the 5-years follow-up (the long term effects of targeted therapy on sinus rhythm maintenance and cardiovascular outcome) will be presented at Late Breaking Clinical Trial session on Friday April 23rd between 17:55-18:50h.
Bao-Oanh Nguyen, Michiel Rienstra and Isabelle van Gelder are our researchers involved.
